Fulgent Genetics, Inc. (FLGT) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Lifestance Health Group, Inc.

Pediatrix Medical Group, Inc.

Addus HomeCare Corp.

NeoGenomics, Inc.

U.S. Physical Therapy, Inc.

RadNet, Inc.

Ginkgo Bioworks Holdings, Inc.

Hims & Hers Health, Inc.

OPKO Health, Inc.

Fulgent Genetics, Inc.

Celldex Therapeutics, Inc.

Why is Fulgent Genetics, Inc. ?

The company has declared negative results for the last 3 consecutive quarters

INTEREST(HY) At USD 0.08 MM has Grown at 145.16%
OPERATING CASH FLOW(Y) Lowest at USD -83.69 MM
PRE-TAX PROFIT(Q) At USD -27.25 MM has Fallen at -52.82%

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -6.20%, its profits have fallen by -53.2%

Consistent Underperformance against the benchmark over the last 3 years

Along with generating -6.20% returns in the last 1 year, the stock has also underperformed S&P 500 in each of the last 3 annual periods

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Fulgent Genetics, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Fulgent Genetics, Inc.

-6.2%

-0.10

60.15%

S&P 500

22.36%

1.70

13.18%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-5.21%

EBIT Growth (5y)

-179.32%

EBIT to Interest (avg)

100.00

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.28

Sales to Capital Employed (avg)

0.26

Tax Ratio

15.43%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

66.82%

ROCE (avg)

43.94%

ROE (avg)

17.45%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.44

EV to EBIT

-1.70

EV to EBITDA

-2.32

EV to Capital Employed

0.20

EV to Sales

0.48

PEG Ratio

Dividend Yield

ROCE (Latest)

-11.68%

ROE (Latest)

-4.65%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

Bullish

No Signal

Bollinger Bands

Mildly Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Bullish

Dow Theory

No Trend

Mildly Bearish

OBV

No Trend

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

4What is working for the Company

NET PROFIT(HY)

Higher at USD -48.89 MM

INVENTORY TURNOVER RATIO(HY)

Highest at 548.18 times

NET SALES(Q)

Highest at USD 85.39 MM

-29What is not working for the Company

INTEREST(HY)

At USD 0.08 MM has Grown at 145.16%

OPERATING CASH FLOW(Y)

Lowest at USD -83.69 MM

PRE-TAX PROFIT(Q)

At USD -27.25 MM has Fallen at -52.82%

RAW MATERIAL COST(Y)

Grown by 32.7% (YoY

CASH AND EQV(HY)

Lowest at USD 533.33 MM

NET PROFIT(Q)

Lowest at USD -27.09 MM

EPS(Q)

Lowest at USD -1.05

Here's what is working for Fulgent Genetics, Inc.

Net Sales

Highest at USD 85.39 MM

in the last five periods

MOJO Watch

Near term sales trend is positive

Net Sales (USD MM)

Inventory Turnover Ratio

Highest at 548.18 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Depreciation

Highest at USD 7.68 MM

in the last five periods

MOJO Watch

The expenditure on assets done by the company may have gone into operation

Depreciation (USD MM)

Depreciation

At USD 7.68 MM has Grown at 27.93%

period on period (QoQ)

MOJO Watch

The expenditure on assets done by the company has gone into productive use which should positively reflect in the future sales

Depreciation (USD MM)

Here's what is not working for Fulgent Genetics, Inc.

Interest

At USD 0.08 MM has Grown at 145.16%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Pre-Tax Profit

At USD -27.25 MM has Fallen at -52.82%

over average net sales of the previous four periods of USD -17.83 MM

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit

At USD -27.09 MM has Fallen at -78.06%

over average net sales of the previous four periods of USD -15.21 MM

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

Operating Cash Flow

Lowest at USD -83.69 MM and Fallen

In each year in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Net Profit

Lowest at USD -27.09 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is negative

Net Profit (USD MM)

EPS

Lowest at USD -1.05

in the last five periods

MOJO Watch

Declining profitability; company has created lower earnings for shareholders

EPS (USD)

Cash and Eqv

Lowest at USD 533.33 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Raw Material Cost

Grown by 32.7% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales